

WOAH Reference Laboratory Reports Activities 2022

Activities in 2022

This report has been submitted : 8 mars 2023 11:08

Laboratory Information

Name of disease (or topic) for which you are a designated WOAH Reference Laboratory:	Equine Rhinopneumonitis
Address of laboratory:	Irish Equine Centre, Johnstown, Naas, Co Kildare, Ireland
Tel.:	045866266
E-mail address:	acullinane@irishequinecentre.ie
Website:	
Name (including Title) of Head of Laboratory (Responsible Official):	Deborah Grey MBA CEO
Name (including Title and Position) of WOAH Reference Expert:	Professor Ann Cullinane MVB PhD Head of Virology
Which of the following defines your laboratory? Check all that apply:	Registered Charity

TOR1: DIAGNOSTIC METHODS

1. Did your laboratory perform diagnostic tests for the specified disease/topic for purposes such as disease diagnosis, screening of animals for export, surveillance, etc.? (Not for quality control, proficiency testing or staff training)

Yes

Diagnostic Test	Indicated in WOAH Manual (Yes/No)	Total number of test performed last year	
Indirect diagnostic tests		Nationally	Internationally
CFT	Yes	200	420
SNT	Yes	0	377

Direct diagnostic tests		Nationally	Internationally
PCR	Yes	2428	18

TOR2: REFERENCE MATERIAL

2. Did your laboratory produce or supply imported standard reference reagents officially recognised by WOA?H?

No

3. Did your laboratory supply standard reference reagents (nonWOAH-approved) and/or other diagnostic reagents to WOA?H Members?

Yes

TYPE OF REAGENT AVAILABLE	RELATED DIAGNOSTIC TEST	PRODUCED/ PROVIDE	AMOUNT SUPPLIED NATIONALLY (ML, MG)	AMOUNT SUPPLIED INTERNATIONALLY (ML, MG)	NO. OF RECIPIENT WOA?H MEMBER COUNTRIES	COUNTRY OF RECIPIENTS
Equine Herpesvirus 1 (EHV1)	PCR	Produced	0	1ml	1	America
EHV1 DNA	PCR	Produced	0	3ml	1	America
Equine Herpesvirus 4 (EHV4)	PCR	Produced	0	1ml	1	America
EHV4 DNA	PCR	Produced	0	3ml	1	America

4. Did your laboratory produce vaccines?

No

5. Did your laboratory supply vaccines to WOA?H Members?

No

TOR3: NEW PROCEDURES

6. Did your laboratory develop new diagnostic methods for the designated pathogen or disease?

No

7. Did your laboratory validate diagnostic methods according to WOA?H Standards for the designated pathogen or disease?

No

8. Did your laboratory develop new vaccines for the designated pathogen or disease?

No

9. Did your laboratory validate vaccines according to WOA?H Standards for the designated pathogen or disease?

No

TOR4: DIAGNOSTIC TESTING FACILITIES

10. Did your laboratory carry out diagnostic testing for other WOA?H Members?

Yes

NAME OF WOA?H MEMBER COUNTRY	DATE	WHICH DIAGNOSTIC	NO. SAMPLES RECEIVED FOR PROVISION OF	NO. SAMPLES RECEIVED FOR PROVISION OF
------------------------------	------	------------------	---------------------------------------	---------------------------------------

SEEKING ASSISTANCE		TEST USED	DIAGNOSTIC SUPPORT	CONFIRMATORY DIAGNOSES
HUNGARY	2022-07-28	PCR and Sequencing		20
FRANCE	2023-03-24	CFT and SNT	9	
FRANCE	2022-04-14	CFT and SNT	6	
FRANCE	2022-05-05	CFT and SNT	2	
FRANCE	2022-09-21	CFT and SNT	6	
FRANCE	2022-10-14	CFT and SNT	4	
FRANCE	2022-10-20	CFT and SNT	27	
	2022-11-24	CFT and SNT	27	
SPAIN	2022-01-06	CFT and SNT	50	
	2022-03-31	CFT and SNT	34	
SPAIN	2022-04-22	CFT and SNT	24	
SPAIN	2022-06-30	CFT and SNT	168	
SPAIN	2022-03-04	CFT and SNT	20	
UNITED KINGDOM	2022-01-04	CFT	30	
UNITED KINGDOM	2022-03-23	CFT	10	
UNITED KINGDOM	2022-06-17	CFT	2	
UNITED KINGDOM	2022-11-11	PCR	1	
UNITED KINGDOM	2022-11-21	PCR	1	
UNITED KINGDOM	2022-06-17	PCR	2	
UNITED KINGDOM	2022-03-29	PCR	1	
UNITED KINGDOM	2022-04-01	PCR	1	
UNITED KINGDOM	2022-01-13	PCR	3	
	2022-12-16	PCR	1	

11. Did your laboratory provide expert advice in technical consultancies on the request of an WOAHP Member?

Yes

NAME OF THE WOAHP MEMBER COUNTRY RECEIVING A TECHNICAL CONSULTANCY	PURPOSE	HOW THE ADVICE WAS PROVIDED
TURKEY	PCR equipment	E mail
SWITZERLAND	FEI- Introduction of mandatory vaccination	Videoconferences
SWEDEN	Terminology	E-mail

TOR5: COLLABORATIVE SCIENTIFIC AND TECHNICAL STUDIES

12. Did your laboratory participate in international scientific studies in collaboration with WOAHP Members other than the own?

Yes

Title of the study	Duration	PURPOSE OF THE STUDY	PARTNERS (INSTITUTIONS)	WOAHP MEMBER COUNTRIES INVOLVED OTHER THAN YOUR COUNTRY
Comparison of Four Primary Vaccination Protocols	2021-2024	Compare humoral response of foals to different vaccination	University of Hanover and Cornell College of Veterinary Medicine	UNITED STATES OF AMERICA

regimes

TOR6: EPIZOOLOGICAL DATA

14. Did your Laboratory collect epidemiological data relevant to international disease control?

Yes

IF THE ANSWER IS YES, PLEASE PROVIDE DETAILS OF THE DATA COLLECTED:

Epidemiological data and virus characterisation

15. Did your laboratory disseminate epidemiological data that had been processed and analysed?

Yes

IF THE ANSWER IS YES, PLEASE PROVIDE DETAILS OF THE DATA COLLECTED:

As above

16. What method of dissemination of information is most often used by your laboratory? (Indicate in the appropriate box the number by category and list the details in the box)

a) Articles published in peer-reviewed journals:

0

b) International conferences:

2

Presentation at Equine Veterinarian Congress in Czech Republic - "Equine Herpesviruses - a Constant Threat to Equine Health" December 2022 Prague

Presentation to FEEVA Surveillance Network entitled Equine Influenza and Equine Herpesvirus Mandatory Vaccination – Protectiveness V Legitimacy

c) National conferences:

1

Irish Equine Veterinary Association - Presentation "Update on Current Equine Virology Issues" November 2022

d) Other (Provide website address or link to appropriate information):

1

Provided incidence figures to Department of Agriculture for inclusion in 6 monthly reports to WOA

TOR7: SCIENTIFIC AND TECHNICAL TRAINING

17. Did your laboratory provide scientific and technical training to laboratory personnel from other WOAAH Members?

No

TOR8: QUALITY ASSURANCE

18. Does your laboratory have a Quality Management System?

Yes

Quality management system adopted	Certificate scan (PDF, JPG, PNG format)	
ISO 17025	pdf	the-irish-equine-foundation-ltd-151t.pdf

19. Is your quality management system accredited?

Yes

Test for which your laboratory is accredited	Accreditation body
CFT	INAB
SNT	INAB
real time PCR	INAB

20. Does your laboratory maintain a "biorisk management system" for the pathogen and the disease concerned?

Yes

Initial laboratory processing of all unknown diagnostic specimens is carried out in calibrated/certified Biosafety Level (BCL)-2, which are decontaminated regularly and after use. Virus culture/inoculation is carried out in dedicated BCL-2 hoods. A precautions checklist worksheet is completed before this work is commenced. Disposable coats must be worn. All liquid waste is decontaminated and exposed to UV irradiation for a minimum of 20 minutes. Biological waste is collected and sealed in a double-autoclave bag. All staff are trained with regard to segregation, handling, storage and transport of clinical waste. Any materials containing live virus are soaked overnight in a disinfectant of proven efficacy against herpesviruses. All biological waste liquids are decontaminated prior to drain disposal. All biological waste solids are discarded as regulated medical waste and autoclaved or disinfected as appropriate. All sharps (e.g. pipette tips, pipettes, needles, syringes, broken glassware or any object that can puncture the skin) are disposed of in biohazard sharps containers provided for this purpose. Laboratory clinical soft waste and clinical solid waste is collected weekly a licensed waste management company. Clinical soft waste and clinical solid waste is treated by a steam disinfection process, at log 6 decimal reduction. Infectious samples shipped by road and air are classified (e.g. biological substance category B UN3373), marked, packed, labelled and documented according to ADR and IATA regulations. All accidents, bio hazardous exposures and work related illnesses are reported to the Health and Safety manager (biosafety and biosecurity officer)/laboratory head

TOR9: SCIENTIFIC MEETINGS

21. Did your laboratory organise scientific meetings related to the pathogen in question on behalf of WOAAH?

No

22. Did your laboratory participate in scientific meetings related to the pathogen in question on behalf of WOAAH?

Yes

--	--	--	--	--

Title of event	Date (mm/yy)	Location	Role (speaker, presenting poster, short communications)	Title of the work presented
FEEVA Surveillance Network	2022-10-11	Zagreb	Speaker	• Equine Influenza and Equine Herpesvirus Mandatory Vaccination – Protectiveness V Legitimacy

TOR10: NETWORK WITH WOAHP REFERENCE LABORATORIES

23. Did your laboratory exchange information with other WOAHP Reference Laboratories designated for the same pathogen or disease?

No

24. Are you a member of a network of WOAHP Reference Laboratories designated for the same pathogen?

No

25. Did you organise or participate in inter-laboratory proficiency tests with WOAHP Reference Laboratories designated for the same pathogen?

No

26. Did your laboratory collaborate with other WOAHP Reference Laboratories for the same disease on scientific research projects for the diagnosis or control of the pathogen of interest?

No

TOR11: OTHER INTERLABORATORY PROFICIENCY TESTING

27. Did your laboratory organise or participate in inter-laboratory proficiency tests with laboratories other than WOAHP Reference Laboratories for the same pathogen?

Yes

Purpose for inter-laboratory test comparisons ¹	Role of your reference laboratory (organizer/participant)	No. participating laboratories	Region(s) of participating WOAHP Member Countries
Assessment of competence - EHV1 SNT	Organiser	1	Europe
Assessment of competence - EHV1 and EHV4 PCR	Organiser	2	Asia and Pacific Europe
Assessment of competence and maintenance of accreditation - EHV1 and EHV4 PCR, CFT and SNT	Co-Organiser	2	Europe

TOR12: EXPERT CONSULTANTS

28. Did your laboratory place expert consultants at the disposal of WOAHP?

Yes

--	--	--

KIND OF CONSULTANCY	Location	SUBJECT (FACULTATIVE)
Vice President of BSC	Videoconference and HQ	International Standards for Diagnostic Tests and Vaccines
Chair of FAO-WOAH Advisory Group	Videoconference	Viral evolution of SARS-CoV-2 in animals
WOAH representative on WHO Advisory Group on viral evolution of SARS-CoV-2	Videoconference	Monitoring key mutations and their implications for public health
Chair of WOAH Expert Surveillance Panel for Equine Influenza	Videoconference	Characterisation of emerging strains and implications for vaccine composition
Participant at WOAH Meeting	Videoconference	Terms of Reference for future WOAH group Emerging Disease Threats
Participant at WOAH Meeting	Videoconference	Impact of evolving technology on laboratory sustainability
WOAH representative at WHO meeting	Geneva	Global Genomic Surveillance Strategy

29. Additional comments regarding your report:

No